Can Microdosing Be Dangerous?
- Anahita Anais
- Jul 19, 2021
- 7 min read
By Anahita Anais, Nervous System and Microdosing Expert, founder of Microdose Guru.
Last reviewed: June 2026.
Short answer: microdosing is not free of risk, and "low dose" does not mean "no risk." Most people who microdose psilocybin or LSD report no serious harm, but the long-term safety of taking these substances regularly has never been formally established, and there are situations where microdosing is genuinely unsafe. This article is educational and is not medical advice. Talk to your physician before changing any medication or starting a microdosing practice.
It also matters where you stand legally. Psilocybin is a Schedule I controlled substance under U.S. federal law, which the DEA defines as having a high potential for abuse and no currently accepted medical use. LSD carries the same classification. That status is one reason quality control is poor in the unregulated market, and it shapes much of the risk discussion below.
Microdosing is also not a fringe practice anymore. A nationally representative survey by RAND, 2026 estimated that roughly 10 million U.S. adults, about 3.7 percent, used a psychedelic at a microdose level in 2025. The scale is one more reason to be clear-eyed about where the real risks sit.
The Research
The honest starting point is how little we know. Most of what exists on microdosing comes from self-report surveys and observational studies, not controlled safety trials. One of the most cited surveys, Anderson et al., PLOS ONE, 2019, tracked people who microdose and found that the reported benefits sat alongside real downsides. Participants also reported anxiety, physical discomfort, and disrupted focus. Because people in these studies recruit themselves from enthusiast communities and report their own doses, the results lean more positive and cannot tell us how common adverse effects actually are.
What the survey data could not settle, a placebo-controlled design later complicated. In the largest controlled microdosing experiment to date, Szigeti et al., eLife, 2021 had 191 participants self-blind by mixing their own microdoses with identical placebo capsules. People improved across psychological measures, but the placebo group improved just as much, with no reliable difference between them. That does not prove microdosing does nothing for everyone, but it is a strong signal that much of the reported benefit is expectation rather than the substance. It also reframes the risk math: if a meaningful share of the upside is placebo, then the physical risks below are not offset by a guaranteed gain.
A canonical microdose is small by design. For dried Psilocybe cubensis, that means roughly 0.05 to 0.30 g, and for LSD roughly 5 to 20 micrograms (µg, not mg). That is well below the dose associated with an acute, intoxicating experience. But a small dose is not a safe dose in every context. The long-term safety of repeated dosing has not been formally established, and the contraindications below apply at any dose.
Cardiovascular conditions. Psilocybin and LSD act on serotonin receptors, including the 5-HT2B receptor, which is involved in heart valve tissue. Drugs that overstimulate this receptor over time have caused valve damage in the past. A review of this question, Rouaud, Calder & Hasler, Journal of Psychopharmacology, 2024, notes that frequent, sustained microdosing may carry a theoretical risk of cardiac fibrosis and valve changes, and flags it as an open question rather than a proven harm. A later animal study, Korkmaz et al., ACS Pharmacology & Translational Science, 2025, gave mice repeated subhallucinogenic doses of LSD and found no valve changes, while the known cardiotoxins used for comparison did damage the heart. That is reassuring but limited: it is one study, in mice, and it does not resolve the human question. If you have a known heart condition, this is a conversation for your cardiologist before anything else.
SSRIs, MAOIs, and serotonin syndrome. Combining a serotonergic psychedelic with antidepressants that already raise serotonin levels can, in principle, contribute to serotonin syndrome, a potentially life-threatening reaction driven by too much serotonin activity in the body. The classic clinical reference, Boyer & Shannon, New England Journal of Medicine, 2005, describes how it arises and why drug combinations are a common trigger. MAOIs are the highest-concern class here. This is not a risk to manage on your own, and if you take an antidepressant, start with what to know about microdosing while on antidepressants.
Personal or family history of psychosis. A personal or family history of psychotic disorders is a widely recognized reason for caution with psychedelics, because these substances can surface or worsen latent vulnerability. This is consistently treated as a contraindication in the clinical-trial literature, including the controlled-studies review Polito & Liknaitzky, Biological Psychiatry: CNNI, 2024.
Persistent perceptual changes (HPPD). A smaller number of people develop lasting visual disturbances after using hallucinogens, a condition known as hallucinogen persisting perception disorder. A review of what is known, Martinotti et al., Brain Sciences, 2018, describes the visual symptoms and notes that the prevalence is genuinely uncertain. It is uncommon, but it is real.
Other drug interactions. Beyond SSRIs and MAOIs, caution is warranted with lithium (case reports describe seizures when combined with psychedelics), tramadol, and stimulants. Stacking psychedelics with MDMA or other recreational substances further raises the risk rather than lowering it. Combining psychedelics with other drugs is its own subject, covered in the precautions around mixing substances.
Pregnancy and breastfeeding. No safety data has established that microdosing is safe during pregnancy or breastfeeding. In the absence of evidence, the responsible default is to avoid it.
Sourcing and dose accuracy. Because the market is unregulated, two practical risks sit underneath all of the above: you may not have what you think you have (mislabeled or contaminated material), and you may not be taking the dose you think you are. The clearest recent illustration is the 2024 outbreak tied to Diamond Shruumz, a brand of "microdosing" chocolate edibles. According to the CDC, 2025, these products were linked to 180 illnesses across 34 states, with 73 hospitalizations and three deaths. Testing found a mix of substances that were not what the label implied, including muscimol, a prescription drug, and kava compounds. No one buying those bars was dosing what they thought they were dosing. Inconsistent material makes every other safety judgment harder, which is also why getting the dose itself right depends on knowing what you actually have.
A Direct Word On Antidepressants
This is the most important caution on the page, because it is the one most often handled badly.
Do not stop or reduce a prescribed antidepressant on your own, and never do it as a way to start microdosing. Antidepressant discontinuation carries real risks. A systematic review and meta-analysis by Henssler et al., The Lancet Psychiatry, 2024, found that roughly one in six to seven people who stop antidepressants experience discontinuation symptoms, and that figure does not account for the separate risk of the original condition relapsing. Tapering, when it happens, must be planned and supervised by the physician who prescribed the medication. If and only if your doctor has supervised a change to your medication, a qualified practitioner can help you think through whether microdosing is appropriate afterward.
No one should frame stopping psychiatric medication as a path to microdosing. That framing gets the priority backwards and can be dangerous.
Related on Microdose Guru
When To Talk To A Doctor First
Speak with your physician before considering microdosing if any of these apply to you:
You take an SSRI, SNRI, MAOI, lithium, tramadol, or another serotonergic medication.
You have a heart condition or a history of valve problems.
You have a personal or family history of psychosis or bipolar disorder.
You are pregnant, trying to conceive, or breastfeeding.
You are considering any change to a prescribed psychiatric medication.
These are not the only situations that warrant medical input, but they are the clearest. When in doubt, ask first.
Frequently Asked Questions
Is Microdosing Safer Than A Full Dose?
In some ways, yes: the doses involved (0.05 to 0.30 g of dried Psilocybe cubensis, or 5 to 20 µg of LSD) keep most people well below the range linked to an acute, intoxicating experience, so the risk of a frightening trip is low. But "smaller" is not the same as "safe." The contraindications on this page (heart conditions, serotonergic medications, a history of psychosis, pregnancy) apply at any dose, and frequent repeat dosing raises questions a single experience does not.
Can Microdosing Damage Your Heart?
The concern is theoretical, not established. Psilocybin and LSD touch the same 5-HT2B receptor as some older drugs that caused valve damage with sustained use. A 2024 review flagged this as an open question, and a 2025 mouse study found no valve changes at microdoses. There is no good long-term human data either way, so anyone with a known heart condition should clear it with a cardiologist first.
Can I Microdose While Taking An Antidepressant?
Not without your prescriber. SSRIs, SNRIs, and especially MAOIs raise serotonin, and combining them with a serotonergic psychedelic carries a theoretical risk of serotonin syndrome. Just as important: never stop or taper a prescribed antidepressant on your own to make room for microdosing. That is the single most dangerous move people make in this area.
Does Microdosing Work, Or Is It Placebo?
The best controlled evidence to date suggests a large share of the reported benefit is placebo. In a 2021 self-blinding study, people who took real microdoses improved, but so did people who unknowingly took placebos, by about the same amount. That does not mean nothing is happening for anyone, but it does mean the upside is less certain than enthusiast surveys suggest.
How Do I Know My Microdose Is What The Label Says?
Often, you cannot, which is the core problem. The market is unregulated, and the 2024 Diamond Shruumz outbreak (180 illnesses, 73 hospitalizations, three deaths) showed how badly "microdosing" products can be mislabeled and adulterated. Inconsistent material undermines every other safety decision, which is why sourcing and dose accuracy belong at the top of any harm-reduction checklist, alongside an honest look at what microdosing can and cannot do for you.
The Bottom Line
Microdosing is not inherently catastrophic, and the small doses involved keep most people well below the range linked to acute harm. But "low dose" is not the same as "safe," the long-term picture is genuinely unstudied, much of the benefit may be placebo, and the contraindications above are not optional fine print. The harm-reduction stance is straightforward: know your contraindications, never modify your prescribed medication amount or schedule without consulting your doctor, source carefully, and treat your own caution as part of the practice rather than an obstacle to it.
If you want a grounded, contraindication-aware way to think through dosing rather than guessing, the Microdose Guru Protocol Guide walks through safe-dose ranges and the cautions on this page in practical detail. If you are not ready to commit to that, start with the free mini-guide.
